{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040009","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.591756+00:00","generated_at":"2026-06-08T06:41:39.837339+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pulmatrix Q3 2023 net loss $3.8M; cash $21.3M, runway into Q1 2025","bullets":["Revenue $1.8M (-$0.1M YoY); net loss $3.8M ($1.03/share) vs $5.1M loss in prior year.","Cash $21.3M, down from $35.6M at Dec 2022; projected runway into Q1 2025.","PUR1900 Phase 2b in ABPA ongoing; topline data expected H2 2024.","PUR3100 IND cleared for Phase 2 in acute migraine; study start contingent on financing.","PUR1800 Phase 1b completed; seeking partnership for Phase 2."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040009","json":"https://secwatch.observer/filing/0001493152-23-040009.json","markdown":"https://secwatch.observer/filing/0001493152-23-040009.md","text":"https://secwatch.observer/filing/0001493152-23-040009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315223040009/0001493152-23-040009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315223040009/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:41:39.837339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d2d24f56363b98a661c6d610929c8c87e2552a93","claim":"Pulmatrix, Inc. reported the third fiscal quarter ended September 30, 2023 results: revenue $1.8 million.","evidence_excerpt":"plans to pursue partnership opportunities to advance PUR1800 into a potential Phase 2 clinical trial. Third Quarter 2023 Financial Results Revenues decreased $0.1 million to $1.8 million for the three months ended September 30, 2023 compared to $1.9 million for the three months ended September 30, 2022. The decrease is related to the Company’s revenues recognized","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574235/000149315223040009/0001493152-23-040009-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third fiscal quarter ended September 30, 2023"},{"label":"Revenue","value":"$1.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}